Business
Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention
Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease Therapeutic\nNEW YORK, April 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company will be presenting at the BIO International Convention taking place June 13 - 16, 2022 in San Diego, California.\n\n \n \n \n \n \n \n\n \nDr. Stefanie Johns, Chief Scientific Officer, will be presenting an overview of the Hoth Therapeutics pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's disease therapeutic under development.\nTo learn more about the BIO International Convention or register to attend, visit the conference website. To attend Dr. Johns' session, please check our website for the presentation time closer to the conference date.\nAbout Hoth Therapeutics, Inc.\nHoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer's Disease, atopic dermatitis, and other indications. To learn more, please visit https://ir.hoththerapeutics.com/.\nForward-Looking Statement\nThis press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the glob...